
    
      The study will include a screening period of up to 60 days (Day -60 to -1), a primary
      analysis treatment period (Day 1 to Week 52), a long-term treatment period (Week 53 to Week
      104), and an extension period continuing up to Week 364 (for patients who continue to
      demonstrate the clinical benefit from eliglustat monotherapy at Week 104). After study
      completion, patients will be encouraged to enroll in the International Collaborative Gaucher
      Group (ICGG) Gaucher Registry.
    
  